Commercial niche Target hospital and surgical oncology settings with Barhemsys and amisulpride-based therapies to address postoperative nausea and chemotherapy-induced nausea, leveraging Acacia Pharma's focus on acute care patients.

US market entry capitalize on past US launch activity and distribution readiness to expand hospital channels, wholesalers, and specialty distributors for acute care antiemetic products in the United States.

Strategic acquisitions Monitor and engage with potential licensing or collaboration opportunities following Acacia’s acquisition history, exploring co-commercialization or in-licensing of amisulpride-based assets to accelerate market penetration.

Financing leverage Leverage the company’s $64M funding history to support co-marketing, regional launches, and expanded sales teams in target geographies, aligning with revenue targets in the $1M-$10M range.

Product portfolio Position value proposition around BARHEMSYS and related antiemetic candidates to hospitals and cancer centers emphasizing rapid onset, perioperative care, and compatibility with chemotherapy regimens.